CEO Lawrence V. Bruno highlighted that "Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core's technical and geographic ...

Fintel reports that on March 12, 2025, Citigroup upgraded their outlook for Core Laboratories (NYSE:CLB) from Sell to Neutral. As of March 4, 2025, the average one-year price target for Core ...

Most readers would already be aware that Core Laboratories' (NYSE:CLB) stock increased significantly by 46% over the past three months. Given that the market rewards strong financials in the long-term ...

Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago. These figures are ...

Good day, and welcome to the Core Laboratories Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Larry Bruno, ...

Core Laboratories Inc. CLB reported second-quarter 2025 adjusted earnings of 19 cents per share, which beat the Zacks Consensus Estimate of 18 cents. However, the bottom line decreased from the ...

Core Laboratories is in good financial health. At the last reporting period, the firm had $16 million of cash on hand and $180 million of long-term debt. 2022 net debt/adjusted EBITDA was elevated at ...